REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
